Article Sidebar

Submitted
Apr 13, 2021
Published
Apr 13, 2021
Download
PDF
Statistic
Read Counter : 49 Download : 26

Main Article Content

Abstract

Unlimited commercial production of antibiotics and their ever increasing use in our day to day life has led to the evolution of a class of organism known as multi-drug resistance organisms (MDRO). Multi drug resistance (MDR) is a condition in which a particular disease causing microorganism (virus, bacteria, fungi and parasites) becomes resistant to antimicrobials (antivirals, antibiotics or antimicrobics). The present Chapter will focus on the cause and mechanism of MDR in bacteria and their prevention, if any, such as combination antibiotic therapy. These bacteria range from urgent threat level such as Neisseria gonorrhoeae to serious threat level such as Streptococcus pneumonia and also includes microorganism with a concerning threat level such as Group AStreptococcus. The discussion also includes MDR in viruses (such as Hepatitis B) and their prevention, if any.

Keywords

Multi drug resistance Antibiotics Antiviral drugs R plasmids Efflux pumps WHO

Article Details

How to Cite
Aritra Bhattacharyya, Sharmily Chakraborty, & Tapan Kumar Chatterjee. (2021). The third world war: man versus drug resistant virus and bacteria. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(1), 28-37. https://doi.org/10.61096/ijrpp.v6.iss1.2017.28-37
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Nikaido H. Multi drug resistance in bacteria.Annu Rev Biochem. 78, 2009, 119–146.
  2. [2]. U.S. Department of Health and Human Services, Centre for Disease Control and Prevention, Antibiotic Resistance threats in the United States, 2013.
  3. [3]. World Health Organization, Antimicrobial resistance global report on surveillance, 2014.
  4. [4]. ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food- producing animals. Stockholm/Parma/London: ECDC/EFSA/EMA, 2015. EFSA Journal pp. doi:10.2903/j.efsa.2015.4006. 13(1), 2015, 4006, 114
  5. [5]. Tanwar J, Das S, Fatima Z, Hameed S.Multidrug Resistance: An Emerging Crisis.Interdisciplinary Perspectives on Infectious Diseases. 2014, 541340
  6. [6]. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis b infection. 2015.
  7. [7]. Strasfeld L, Chou S.Antiviral Drug Resistance: Mechanisms and Clinical Implications. Infect Dis Clin North Am. 24(2), 2010, 413–437.
  8. [8]. Sellar RS, Peggs KS. Management of multidrug-resistant viruses in the immunocompromised host. British Journal of Haematology. 156, 2012, 559–572.
  9. [9]. Bonomo RA, Szabo D. Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa. Clinical Infectious Diseases. 43, 2006, S49-S56.
  10. [10]. Lavigne JP, Sotto A, Nicolas Chanoine MH, Bouziges N, Bourg G, DavinRegli A, Pages JM. Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in enterobacteraerogenes clinical isolates. ClinMicrobiol Infect. 18, 2012, 539–545.
  11. [11]. Soto SM.Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence. 4(3), 2013, 223–229.
  12. [12]. Nordstrom K, Austin SJ. Mechanisms that contribute to the stable segregation of plasmids. Annu Rev Genet 23, 1989, 37–69.
  13. [13]. Forbes AB, Schaberg DR. Transfer of Resistance Plasmids from Staphylococcus epidermidis to Staphylococcus aureus: Evidence for Conjugative Exchange of Resistance. Journal of bacteriology. 153(2), 1983, 627-634.
  14. [14]. Schaberg DR, Clewell DB, Glatzer L. Conjugative Transfer of R-Plasmids from Streptococcus faecalis to Staphylococcus aureus. Antimicrobial agents and chemotherapy. 22(2), 1982, 204-207.
  15. [15]. Majhi A, Adhikary R, Bhattacharyya A, Mahanti S, Bishayi B. Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin.Antimicrob Agents Chemother. 58(9), 2014, 5164-80
  16. [16]. Majhi A, Kundu K, Adhikary R, Banerjee M, Mahanti S, Basu A, Bishayi B. Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice.J Inflamm (Lond). 11(1), 2014, 5.
  17. [17]. Raviglione M, Marais B, Floyd K, Lönnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SHE, Zumla A. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet. 379, 2012, 1902–13
  18. [18]. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. The American Journal of Gastroenterology. 108, 2013, 478-498.
  19. [19]. Locher HH, Seiler P,Chen X , Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, , Ritz D,Kelly CP,Keck W. In Vitro and In Vivo Antibacterial Evaluation of Cadazolid, a New Antibiotic for Treatment of Clostridium difficile Infections. Antimicrobial Agents and Chemotherapy. 58(2), 2014, 892–900.
  20. [20]. Gaspar MC, Couet W, Olivier JC, Pais AACC, Sousa JJS. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J ClinMicrobiol Infect Dis. 32, 2013, 1231 –1252
  21. [21]. Soliman R, Lynch S, Meader E, Turton JF, Pike R, Hill RLR, Woodford N, Liverfore DM. Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan-resistant Pseudomonas aeruginosa. JMM Case Reports. 2015
  22. [22]. Craig WA, Andes DR. In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa andEnterobacteriaceae , Including Strains with Extended-Spectrum-Lactamases, in the Thighs of Neutropenic Mice.Antimicrobial Agents and Chemotherapy. 57(4), 2013, 1577–1582.
  23. [23]. Hauser C, Hirzberger L, Unemo M, Furrer F, Endimiani A. In vitro Activity of Fosfomycin Alone and in Combination with Ceftriaxone or Azithromycin Against Clinical Neisseria gonorrhoeae Isolates.Antimicrob Agents Chemother. 59(3), 2015, 1605-11.
  24. [24]. Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J, Jensen JS, Ohnishi M, Unemo M. High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea.Antimicrobial Agents and Chemotherapy. 58(9), 2014, 5585–5588.
  25. [25]. Keating TA, Newman JV , Olivier NB, Otterson LG, Andrews B, Boriack-Sjodin PA, Breen JN, Doig P, Dumas J, Gangl E, Green OM, Guler SY, Hentemann MF, McCarthy DJ, Kawatkar S, Kutschke A, Loch JT, Mckenzie AR, Pradeepan S, Prasad S, Martinez-Botella G. In Vivo Validation of Thymidylate Kinase (TMK) with a Rationally Designed, Selective Antibacterial Compound. ACS Chem. Biol. 7, 2012, 1866 – 1872.
  26. [26]. Bhattacharya D, Samanta S, Mukherjee A, Santra CR, Ghosh AN, Niyogi SK, Karmakar P. Antibacterial activities of polyethylene glycol, tween 80 and sodium dodecyl sulphate coated silver nanoparticles in normal and multi-drug resistant bacteria.J NanosciNanotechnol. 12(3), 2012, 2513-21.
  27. [27]. Jesline A, John NP, Narayanan PM, Vani C, Murugan S. Antimicrobial activity of zinc and titanium dioxide nanoparticles against biofilm-producing methicillin-resistant Staphylococcus aureus. ApplNanosci. 5, 2015, 157–162.
  28. [28]. Rishi P, Bhogal A, Arora S, Pandey SK, Verma I, kaur IP. Improved oral therapeutic potential of nanoencapsulatedcryptdin formulation against Salmonella infection. European Journal of Pharmaceutical Sciences. 72, 2015, 27–33.
  29. [29]. Aktaş G, Bozdoğan B, Derbentli S. In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci.Mikrobiyol Bul. 46(3), 2012, 359-65.
  30. [30]. Xu WH, Qin SS, Liu HM. New Synthetic Antibiotics for the Treatment of Enterococcus and Campy-lobacterInfection. Current Topics in Medicinal Chemistry. 14, 2014,21-39
  31. [31]. Messaoudi S, kergourlay G, Dalgalarrando M, Choiset Y, Ferchichi M, Prevost H, Pilet MP, Chobert JM, Manai M, Dousset X. Purification and characterization of a new bacteriocin active against Campylobacter produced by Lactobacillus salivarius SMXD51.Food Microbiology. 32, 2012, 129-134.
  32. [32]. Arnold HM, Sawyer AM, Kollef MH. Use of Adjunctive Aerosolized Antimicrobial Therapy in the Treatment of Pseudomonas aeruginosaand AcinetobacterbaumanniiVentilator-Associated Pneumonia. Respir Care.; 57(8), 2012, 1226 –1233.
  33. [33]. Wang L, Wang YJ, Liu YY, Hui Li, Guo LX, Liu ZH, Shi XL, Hu M. In Vitro Potential of Lycosin-I as an Alternative Antimicrobial Drug for Treatment of Multidrug-Resistant AcinetobacterbaumanniiInfections. Antimicrobial Agents and Chemotherapy. 58(11), 2014, 6999-7002.
  34. [34]. Mangoni ED, Signoriello G, Andini R, Mattei A, Cristoforo MD, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, zarrilli R, Gallo C, Utili R. Colistin and Rifampicin compared with Colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii. A multicentre, randomised, clinical trial. Clinical Infectious Diseases. 57, 2013, 349-358.
  35. [35]. Andrei G1, Snoeck R. Advances in the treatment of varicella-zoster virus infections.AdvPharmacol. 67, 2013, 107-68.
  36. [36]. Goldner T, Hewlett G, Ettischer N, Schaeff HR, Zimmermann H, Lischka P. The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase. Journal of virology. 85(20), 2011, 10884–10893.
  37. [37]. Reiter C, Frohlich T, Zeino M, Marschall M, Bahsi H, Leidenberger M, Freidrich O, Kappes B, Hampel F, Efferth T, Tsogoeva SB. New efficient artemisinin derived agents against human leukemia cells, human cytomegalovirus and Plasmodium falciparum: 2nd generation 1,2,4-trioxane-ferrocene hybrids. European journal of medicinal chemistry. 97, 2015, 164-172.
  38. [38]. Wildum S, Zimmermann H, Lischka P. In Vitro Drug Combination Studies of Letermovir (AIC246, MK-8228) with Approved Anti-Human Cytomegalovirus (HCMV) and Anti-HIV Compounds in Inhibition of HCMV and HIV Replication. Antimicrob Agents Chemother. 59, 2015, 3140–3148
  39. [39]. Kaufman HE, Haw WH. Ganciclovir Ophthalmic Gel 0.15%: Safety and Efficacy of a New Treatment for Herpes Simplex Keratitis.Curr Eye Res. 37(7), 2012, 654-66.
  40. [40]. Bernstein D, Cardin RD, Bravo FJ, Earwood J, Clark JR, Li Y, Mishra P, Li C, Nayak BP, Miller AT, Wu TYH, Cooke MP, Valiante MN. Topical SMIP 7.7, atoll like receptor 7 agonist protects against genital Herpes Simplex virus type-2 disease in the guinea pig model of genital herpes.Antiviral Chemistry & Chemotherapy. 23, 2014, 189-196.
  41. [41]. Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, Distefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM. Protection Provided by a Herpes Simplex Virus 2 (HSV-2) Glycoprotein C and D Subunit Antigen Vaccine against Genital HSV-2 Infection in HSV-1-Seropositive Guinea Pigs.Journal of Virology. 88(4), 2014, 2000 –2010.
  42. [42]. Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R, Hanes J. Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus.Sci. Transl. Med. 4, 2012, 138-79.
  43. [43]. Noska A, Kyrillos R, Hansen G, Hirigoyen D, William DN. The Role of Antiviral Therapy in Immunocompromised Patients with Herpes Simplex Virus Meningitis.Clin Infect Dis. 60(2), 2015, 237-42
  44. [44]. Stavale EJ, Vu H, Sampath A, Ramstedt U, Warfield KL. In Vivo Therapeutic Protection against Influenza A (H1N1) Oseltamivir-Sensitive and Resistant Viruses by the Iminosugar UV-4. PLoS One. 10(3), 2015, e0121662.
  45. [45]. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JCG, Vogel SN. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 497, 2013, 498-503.
  46. [46]. Dobson J, Whitley RJ, Pocock S, Monto AS.Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 385, 2015, 1729-37.
  47. [47]. Shah BM, Schafer JJ, Desimone JA. Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV.Pharmacotherapy. 34(5), 2014, 506-520.
  48. [48]. Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, DeJesus E, Zolopa A, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J. A Randomized, Double- Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/ Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results. J Acquir Immune DeficSyndr. 65(3), 2014, e118-121.
  49. [49]. Kaplan JE, Dominguez K, Jobarteh K, Spira TJ. Postexposure Prophylaxis Against Human Immunodeficiency Virus (HIV): New Guidelines From the WHO: A Perspective. Clinical Infectious Diseases. 60(S3), 2015, S196 – 9.
  50. [50]. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, JJohnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Medicine. 15(1), 2014, 1–85.
  51. [51]. Deal CE, Balazs AB. Vectored antibody gene delivery for the prevention of HIV infection. Current opinion in HIVAIDS. 10(3), 2015, 190-197